TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Simcere Pharmaceutical Group Limited ( (HK:2096) ) just unveiled an announcement.
Simcere Pharmaceutical Group Limited announced the inclusion of its drugs ENZESHU® and ENDOSTAR® in the National Reimbursement Drug List (NRDL) in China. ENZESHU®, a next-generation anti-VEGF monoclonal antibody, is approved for treating certain cancers, while ENDOSTAR®, the only approved endostatin product worldwide, is a cornerstone treatment for advanced non-small cell lung cancer. This inclusion is expected to enhance the company’s market positioning and provide broader access to these treatments for patients.
The most recent analyst rating on (HK:2096) stock is a Buy with a HK$16.30 price target. To see the full list of analyst forecasts on Simcere Pharmaceutical Group Limited stock, see the HK:2096 Stock Forecast page.
More about Simcere Pharmaceutical Group Limited
Simcere Pharmaceutical Group Limited is an innovation and R&D-driven pharmaceutical company with a focus on neuroscience, anti-oncology, autoimmune, and anti-infection therapeutic areas. The company has established a State Key Laboratory of Neurology and Oncology Drug Development and aims to address significant clinical needs through its strategic partnerships and in-house R&D efforts.
Average Trading Volume: 9,588,123
Technical Sentiment Signal: Buy
Current Market Cap: HK$35.02B
Learn more about 2096 stock on TipRanks’ Stock Analysis page.